Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia

Autor(es):Mostrar menos -

Silveira, Douglas R. A. ^{[1, 2, 3]} ; Quek, Lynn ^{[4, 5]} ; Santos, Itamar S. ^[6] ; Corby, Anna ^[4] ; Coelho-Silva, Juan L. ^[7] ; Pereira-Martins, Diego A. ^[7] ; Vallance, Grant ^[5] ; Brown, Benjamin ^[4] ; Nardinelli, Luciana ^{[1, 2]} ; Silva, Wellington F. ^[8] ; Velloso, Elvira D. R. P. ^{[1, 2, 8]} ; Lucena-Araujo, Antonio R. ^[9] ; Traina, Fabiola ^[7] ; Peniket, Andy ^[5] ; Vyas, Paresh ^{[4, 5]} ; Rego, Eduardo M. ^{[1, 2, 8]} ; Bendit, Israel ^{[1, 2]} ; Rocha, Vanderson ^{[5, 1, 2, 8]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Med Sch, HCFMUSP, Serv Hematol Transfus & Cell Therapy, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Med Sch, HCFMUSP, Lab Med Invest Pathogenesis & Directed Therapy On, Sao Paulo - Brazil

^[3] AC Camargo Canc Ctr, Dept Hematol, Sao Paulo - Brazil

^[4] Univ Oxford, Radcliffe Dept Med, Res Council MHU, WIMM, BRC Hematol Theme, Oxford Biomed Res Ctr, Oxford Ct, Oxford - England

^[5] Oxford Univ Hosp NHS Fdn Trust, Dept Hematol, Oxford - England

^[6] Univ Sao Paulo, Fac Med, Internal Med Dept, Sao Paulo - Brazil

^[7] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Med Images Hematol & Clin Oncol, Ribeirao Preto - Brazil

^[8] Univ Sao Paulo, Canc Inst Sao Paulo, Leukemia Unit, Med Sch, Sao Paulo - Brazil

^[9] Univ Fed Pernambuco, Dept Genet, Recife, PE - Brazil

• Tipo de documento: Artigo Científico
• Fonte: BLOOD ADVANCES; v. 4, n. 10, p. 2339-2350, MAY 26 2020.
• Citações Web of Science: 0

Resumo

The 2017 European LeukemiaNet 2017 acute myeloid leukemia (AML) risk stratification (ELN2017) is widely used for risk-stratifying patients with AML. However, its applicability in low- and middle-income countries is limited because of a lack of full cytogenetic and molecular information at diagnosis. Here, we propose an alternative for risk stratification (the Adapted Genetic Risk {[}AGR]), which permits cytogenetic or molecular missing data while retaining prognostic power. We first analyzed 167 intensively treated patients with nonacute promyelocytic leukemia AML enrolled in Sao Paulo, Brazil (Faculdade de Medicina da Universidade de Sao Paulo), as our training data set, using ELN2017 as the standard for comparison with our AGR. Next, we combined our AGR with clinical prognostic parameters found in a Cox proportional hazards model to create a novel scoring system (survival AML score, SAMLS) that stratifies patients with newly diagnosed AML. Finally, we have used 2 independent test cohorts, Faculdade de Medicina de Ribeirao Preto (FMRP; Brazil, n = 145) and Oxford University Hospitals (OUH; United Kingdom, n =157) for validating our findings. AGR was statistically significant for overall survival (OS) in both test cohorts (FMRP, P = .037; OUH, P = .012) and disease-free survival in FMRP (P = .04). The clinical prognostic features in SAMLS were age (>45 years), white blood cell count (<1.5 or >30.0 x 10(3)/mu L), and low albumin levels (<3.8 g/dL), which were associated with worse OS in all 3 cohorts. SAMLS showed a significant difference in OS in the training cohort (P < .001) and test cohorts (FMRP, P = .0018; OUH, P < .001). Therefore, SAMLS, which incorporates the novel AGR evaluation with clinical parameters, is an accurate tool for AML risk assessment. (AU)

• Processo FAPESP: 16/23191-4 - Investigação da Participação de IRS2 na patogênese de neoplasias mieloproliferativas JAK2V617F utilizando modelos murinos
• Beneficiário: Juan Luiz Coelho da Silva
• Linha de fomento: Bolsas no Brasil - Doutorado
• Processo FAPESP: 17/23117-1 - Avaliação da via TP53/TP73 na enxertia de células de leucemia promielocítica aguda em modelo de xenotransplante
• Beneficiário: Diego Antonio Pereira Martins
• Linha de fomento: Bolsas no Brasil - Doutorado